Tactile Medical to Release Second Quarter of Fiscal Year 2025 Financial Results on August 4, 2025
Tactile Medical (NASDAQ: TCMD), a medical technology company specializing in at-home therapies for chronic conditions, has scheduled its Q2 2025 earnings release for August 4, 2025 after market close.
The company will host a conference call with Q&A at 5:00 p.m. Eastern Time on the same day. Investors can participate via phone (877-407-3088 for domestic, 201-389-0927 for international) using access code 13754589, or through a live webcast on the company's investor relations website.
Tactile Medical focuses on treating conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease, helping patients manage their care at home.
Tactile Medical (NASDAQ: TCMD), un'azienda di tecnologia medica specializzata in terapie domiciliari per condizioni croniche, ha programmato la pubblicazione dei risultati del secondo trimestre 2025 per il 4 agosto 2025 dopo la chiusura del mercato.
La società terrà una conference call con sessione di domande e risposte alle 17:00 ora Eastern Time dello stesso giorno. Gli investitori potranno partecipare telefonicamente (877-407-3088 per il mercato domestico, 201-389-0927 per l'internazionale) utilizzando il codice di accesso 13754589, oppure seguire la diretta webcast sul sito web delle relazioni con gli investitori della società.
Tactile Medical si concentra sul trattamento di condizioni quali linfedema, lipedema, insufficienza venosa cronica e malattia polmonare cronica, aiutando i pazienti a gestire la loro cura direttamente a casa.
Tactile Medical (NASDAQ: TCMD), una empresa de tecnología médica especializada en terapias domiciliarias para condiciones crónicas, ha programado la publicación de resultados del segundo trimestre de 2025 para el 4 de agosto de 2025 tras el cierre del mercado.
La compañía realizará una llamada conferencia con sesión de preguntas y respuestas a las 5:00 p.m. hora del Este ese mismo día. Los inversores pueden participar por teléfono (877-407-3088 para llamadas nacionales, 201-389-0927 para internacionales) usando el código de acceso 13754589, o a través de una transmisión en vivo en el sitio web de relaciones con inversionistas de la empresa.
Tactile Medical se enfoca en tratar condiciones como linfedema, lipedema, insuficiencia venosa crónica y enfermedad pulmonar crónica, ayudando a los pacientes a manejar su cuidado desde casa.
Tactile Medical (NASDAQ: TCMD)는 만성 질환을 위한 가정용 치료에 특화된 의료 기술 회사로, 2025년 8월 4일 장 마감 후 2025년 2분기 실적 발표를 예정하고 있습니다.
회사는 같은 날 동부 표준시 오후 5시에 질의응답이 포함된 컨퍼런스 콜을 진행할 예정입니다. 투자자들은 국내 전화(877-407-3088), 국제 전화(201-389-0927)를 통해 접속 코드 13754589를 사용해 참여하거나 회사의 투자자 관계 웹사이트에서 라이브 웹캐스트로 시청할 수 있습니다.
Tactile Medical은 림프부종, 지방부종, 만성 정맥 기능 부전, 만성 폐질환 등 질환 치료에 주력하며, 환자들이 가정에서 치료를 관리할 수 있도록 돕고 있습니다.
Tactile Medical (NASDAQ: TCMD), une entreprise de technologie médicale spécialisée dans les thérapies à domicile pour les affections chroniques, a prévu la publication de ses résultats du deuxième trimestre 2025 pour le 4 août 2025 après la clôture du marché.
La société organisera une conférence téléphonique avec une session de questions-réponses à 17h00, heure de l'Est, le même jour. Les investisseurs peuvent participer par téléphone (877-407-3088 pour les appels nationaux, 201-389-0927 pour les appels internationaux) en utilisant le code d'accès 13754589, ou via une diffusion en direct sur le site web des relations investisseurs de l'entreprise.
Tactile Medical se concentre sur le traitement de maladies telles que le lymphœdème, le lipœdème, l'insuffisance veineuse chronique et la maladie pulmonaire chronique, aidant les patients à gérer leurs soins à domicile.
Tactile Medical (NASDAQ: TCMD), ein Medizintechnikunternehmen, das sich auf Therapien für chronische Erkrankungen zu Hause spezialisiert hat, hat die Veröffentlichung der Ergebnisse für das zweite Quartal 2025 für den 4. August 2025 nach Börsenschluss geplant.
Das Unternehmen wird am selben Tag um 17:00 Uhr Eastern Time eine Telefonkonferenz mit Fragerunde abhalten. Investoren können telefonisch teilnehmen (877-407-3088 für Inland, 201-389-0927 für international) mit dem Zugangscode 13754589 oder über einen Live-Webcast auf der Investor-Relations-Website des Unternehmens.
Tactile Medical konzentriert sich auf die Behandlung von Erkrankungen wie Lymphödem, Lipödem, chronischer venöser Insuffizienz und chronischer Lungenerkrankung und unterstützt Patienten dabei, ihre Versorgung zu Hause zu managen.
- None.
- None.
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2025 financial results will be released after the market closes on Monday, August 4, 2025.
Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 4, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13754589. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.
For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13754589. The webcast will be archived at investors.tactilemedical.com.
About Tactile Systems Technology, Inc. (DBA Tactile Medical)
Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.
Investor Inquiries:
Sam Bentzinger
Gilmartin Group
investorrelations@tactilemedical.com
FAQ
When will Tactile Medical (TCMD) report Q2 2025 earnings?
How can investors access Tactile Medical's Q2 2025 earnings call?
What medical conditions does Tactile Medical (TCMD) treat?
Will there be a replay available for Tactile Medical's Q2 2025 earnings call?
